Business Description
Stayble Therapeutics AB
ISIN : SE0013513652
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.87 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 23.8 | |||||
3-Year EPS without NRI Growth Rate | 24.5 | |||||
3-Year FCF Growth Rate | 34.9 | |||||
3-Year Book Growth Rate | -33.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29.19 | |||||
9-Day RSI | 29.34 | |||||
14-Day RSI | 32.05 | |||||
6-1 Month Momentum % | 94.54 | |||||
12-1 Month Momentum % | 74.06 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.49 | |||||
Quick Ratio | 8.49 | |||||
Cash Ratio | 5.29 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.6 | |||||
Shareholder Yield % | -16.74 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -78.54 | |||||
ROA % | -61.82 | |||||
ROIC % | -157.48 | |||||
ROCE % | -73.73 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.81 | |||||
Price-to-Tangible-Book | 3.26 | |||||
EV-to-EBIT | -1.2 | |||||
EV-to-EBITDA | -1.2 | |||||
EV-to-FCF | -1.1 | |||||
Price-to-Net-Current-Asset-Value | 3.26 | |||||
Earnings Yield (Greenblatt) % | -83.33 | |||||
FCF Yield % | -72.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Stayble Therapeutics AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.032 | ||
Beta | 1.5 | ||
Volatility % | 180.14 | ||
14-Day RSI | 32.05 | ||
14-Day ATR (€) | 0.003831 | ||
20-Day SMA (€) | 0.04017 | ||
12-1 Month Momentum % | 74.06 | ||
52-Week Range (€) | 0.0171 - 0.0834 | ||
Shares Outstanding (Mil) | 43.72 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Stayble Therapeutics AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Stayble Therapeutics AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Stayble Therapeutics AB Frequently Asked Questions
What is Stayble Therapeutics AB(FRA:4K4)'s stock price today?
When is next earnings date of Stayble Therapeutics AB(FRA:4K4)?
Does Stayble Therapeutics AB(FRA:4K4) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |